Shares of Ardelyx (ARDX) jumped 12% following news that Zydus Lifesciences is considering acquiring the company. The potential deal may involve Zydus gaining control of Ardelyx or purchasing specific molecules. To finance this acquisition, Zydus is reportedly planning to raise funds through a qualified institutional placement. Ardelyx, which boasts a market cap of $1.6 billion, did not comment on the speculation, and Zydus also refrained from making any statements regarding the matter.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.